DR. YVONNE M. BUYS
`
`CURRICULUM VITAE
`
`Exhibit 1023
`ARGENTUM
`
`000001
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
` CURRICULUM VITAE
`
`page 2
`
`NAME
`
`OFFICE
`
`Yvonne Margareth Buys
`
`University Health Network
`Toronto Western Hospital
`Department of Ophthalmology and Vision Sciences
`East Wing 6-405
`399 Bathurst Street
`Toronto, Ontario
`M5T 2S8
`
`TELEPHONE
`
`FAX
`
`
`
`E-MAIL
`
`(416) 603-5682
`
`(416) 603-5682
`
`y.buys@utoronto.ca
`
`A. DATE OF PREPARATION: February 27, 2017
`
`B. BIOGRAPHICAL INFORMATION
`
`1. DEGREES
`
`2. DIPLOMAS
`
`2. EMPLOYMENT
`
`Present
`
`2013-present
`
`2009-present
`
`1995-present
`
`Previous
`
`2000-2009
`
`i.
`
`i.
`
`ii.
`
`Doctor of Medicine, with Honors, June 1988, University
`of Toronto, Toronto
`
`Fellowship - Royal College of Surgeons of Canada -
`Ophthalmology, December 1992
`
`Diploma of the American Board of Ophthalmology,
`October 1993
`
`Kensington Eye Institute, Staff Ophthalmologist
`
`Professor, University of Toronto and Staff
`Ophthalmologist, University Health Network, Toronto Western
`Hospital, Department of Ophthalmology and Vision Sciences
`
`Ontario Workers' Compensation Board, Non-Economic Loss roster physician
`for Ophthalmology
`
`Associate Professor, University of Toronto and Staff
`Ophthalmologist, University Health Network, Toronto Western
`Hospital, Department of Ophthalmology and Vision Sciences
`
`000002
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 3
`
`1995-2000
`
`1993-1995
`
`1992-1993
`
`Assistant Professor, University of Toronto and Staff
`Ophthalmologist, University Health Network, Toronto Western
`Hospital, Department of Ophthalmology and Vision Sciences
`
`Lecturer, University of Toronto and Staff Ophthalmologist, The
`Toronto Hospital, Department of Ophthalmology and Vision Sciences
`
`Clinical and Research Glaucoma Fellow, Department of
`Ophthalmology and Vision Sciences, University of Toronto
`
`3. PROFESSIONAL AFFILIATIONS AND ACTIVITIES
`
`i. Membership in Organizations
`
`1988-present
`
`College of Physicians and Surgeons of Ontario
`
`1990-2003
`
`American Academy of Ophthalmology
`
`1992-present
`
`Royal College of Physicians and Surgeons of Canada
`
`1993-present
`
`Association for Research in Vision and Ophthalmology.
`
`1993-present
`
`Canadian Glaucoma Society
`
`1993-present World Glaucoma Association
`
`1993-present
`
`Ontario Medical Association
`
`1995-present
`
`Toronto Hospital Research Institute
`
`1997-present
`
`The American Glaucoma Society
`
`1999-present
`
`Toronto Area Glaucoma Society (TAGS)
`2001-02, President
`
`2003-present
`
`International Society of Ocular Circulation and Oximetry
`
`2005-7
`
`2006-8
`
`2007-9
`
`2007-9
`
`Treasurer and Secretary, Canadian Glaucoma Society
`
`Deputy, Section of Ophthalmology, Ontario Medical Association
`
`President, Canadian Glaucoma Society
`
`Glaucoma Clinical Practice Guidelines Expert Committee Member, Canadian Ophthalmological
`Society
`
`2007-2011
`
`World Glaucoma Day Canadian organizer, World Glaucoma Association
`
`2008-present
`
`Interprofessional Collaboration in Glaucoma Care Committee Member, Canadian Glaucoma
`Society
`
`2009-2011
`
`Past-President, Canadian Glaucoma Society
`
`000003
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 4
`
`2010-2013
`
`Treasurer, Canadian Ophthalmological Society
`
`2010-present
`
`Board Member, Canadian Ophthalmological Society
`
`2011-2013
`
`Specialist Forum Representative for Ophthalmology, Canadian Medical Association
`
`2011-2013
`
`Member, Wait Time Alliance
`
`2013-present
`
`Chair of Continuing Professional Development/Annual Meeting Planning Committee, Canadian
`Ophthalmological Society
`
`2014-present
`
`Planning Committee member, Glaucoma Subspecialty Day, American Academy of
`Ophthalmology
`
`ii. Academic Appointment
`
`1995-present
`
`Associate Member of Institute of Medical Science, University of Toronto
`
`1998 -2002
`
`Examiner for Glaucoma for Certification in Ophthalmology with the Royal
`College of Physicians and Surgeons of Canada
`Representative from University of Toronto. Examiner in Glaucoma. Responsible for
`obtaining multiple choice and short answer questions from all Ophthalmology
`subspecialties from University of Toronto, setting oral exam in Glaucoma, marking short
`answer questions in glaucoma from all English candidates, and giving oral exam in
`glaucoma.
`
`1998-present
`
`Examination Board member for Certification in Ophthalmology with the Royal
`College of Physicians and Surgeons of Canada
`Responsible for writing multiple choice and short answer questions in glaucoma.
`
`2010-1
`
`University Health Network, Research Ethics Board member
`
`iii. University Committees
`
`1991-2, 1996-8 Admissions Committee Member, Department of Ophthalmology and Vision Sciences, University
`of Toronto
`
`1993-present
`
`Resident Evaluations Committee Member, Department of Ophthalmology and Vision Sciences,
`The University Health Network, Toronto Western Hospital
`
`1994-2002
`
`Postgraduate Medical Education Committee Member, Department of Ophthalmology and Vision
`Sciences, University of Toronto
`
`1995-1998
`
`Ophthalmology representative for Faculty Council, University of Toronto
`
`1996-1997
`
`1997-2000
`
`Advisory Committee Member Re Chair of the Department of Ophthalmology and Vision Sciences,
`University of Toronto
`
`Promotions Committee Member, Department of Ophthalmology and Vision Sciences, University
`of Toronto
`
`2002-present
`
`Panel member of University Tribunal, University of Toronto
`
`2003-2014
`
`Ophthalmology Fellowship Committee Member, Department of Ophthalmology and Vision
`Sciences, University of Toronto
`
`000004
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 5
`
`2009-2012
`
`Promotions Committee Member, Department of Ophthalmology and Vision Sciences, University
`of Toronto
`
`iv. Departmental Committees
`
`1993-2007
`
`1994-1997
`
`1994-2001
`
`Head of Technical Service, University Health Network, Toronto Western Hospital, Department of
`Ophthalmology and Vision Sciences
`
`Mentor Program Coordinator, Department of Ophthalmology and Vision Sciences, University of
`Toronto
`
`PGY-1 (First Year Ophthalmology Residents) Coordinator, Department of Ophthalmology and
`Vision Sciences, University of Toronto
`
`2005-present
`
`Co-Director, Glaucoma Unit, Department of Ophthalmology and Vision Sciences, University
`Health Network, Toronto Western Hospital
`
`v. Hospital Committees
`
`1998-2003
`
`Finance Committee Member, Department of Ophthalmology and Vision Sciences, Toronto
`Western Hospital
`
`1998-present
`
`Operating Room Committee Member, Department of Ophthalmology and Vision Sciences,
`Toronto Western Hospital
`
`1999-present
`
`Surgeon of the Month Committee Member, Toronto Western Hospital
`
`1999-present
`
`OR Clinical Management Team Committee Member, Toronto Western Hospital
`
`2004-present
`
`OR Scheduling Working Taskforce, Toronto Western Hospital
`
`2010-1
`
`Research Ethics Board Member, University Health Network
`
`2012-present
`
`Finance Committee Member, Department of Ophthalmology and Vision Sciences, Toronto
`Western Hospital
`
`vi. Editorial Board Member
`
`2000-4
`
`2007-9
`
`Practical Cases on Ophthalmology
`
`International Glaucoma Review, Society Editor
`
`2009-2015
`
`Glaucoma Section Editor, Canadian Journal of Ophthalmology
`
`2014
`
`Guest Editor, Special Issue: Glaucoma Management. Canadian Journal of Ophthalmology 2014;49
`(6).
`
`vii. Journal Reviews
`
`1995-7, 2000,1,2,5-12
`1997, 2001,2
`
`Canadian Journal of Ophthalmology
` Ophthalmic Surgery and Lasers
`
`000005
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 6
`
`1997,8, 2000-12
`1999
`1999, 2000
`2003
`2003, 6-12
`2004,5, 9, 10
`2008
`2008
`2009, 10
`2010
`
`
`viii. Other Reviews
`
` Journal of Glaucoma
` Pediatrics
` Comprehensive Ophthalmology Update
` Clinical Neuropharmacology
` Ophthalmology
` Graefes Archive for Clinical and Experimental Ophthalmology
` Archives of Ophthalmology
`Ophthalmic Research
`Eye
`British Journal of Ophthalmology
`
`2002,5-12
`
`Glaucoma Research Society of Canada
`
`C. ACADEMIC HISTORY
`
`1. RESEARCH ENDEAVORS
`Only research ongoing since my last promotion is included.
`
`2009-2011
`
`Complementary and Alternative Therapies for Glaucoma (Principal
`Investigator)
`Complementary and alternative medicine (CAM) is defined by the
`National Institutes of Health (NIH) as a diverse group of medical and
`health care systems, practices, and products that are not presently
`considered to be part of conventional medicine. CAM can be grouped
`into four domains: whole medical systems (homeopathy and
`naturopathic medicine), mind-body medicine (meditation), biologically
`based practices (dietary supplements, vitamins and herbal products), and
`manipulative and body-based practices (massage and chiropractic
`medicine).
`Despite the lack of public funding for unconventional medical therapies
`in Canada, surveys by Health Canada and the Fraser Institute have
`indicated that over 70% of adult Canadians have utilized CAM at some
`point in their lives and over 50% currently use at least one CAM therapy
`or medication.
`The use of CAM in glaucoma is an interesting and controversial topic. It
`is now well established that glaucoma has a complex pathophysiology
`that extends beyond intraocular pressure (IOP). Although increased IOP
`is the most important risk factor for the development and progression of
`glaucoma, many patients have progressive optic neuropathy and visual
`field loss despite lowering of IOP to normal levels. As a result, there has
`been growing interest in potential therapies that may slow the
`progression of glaucoma by alternative mechanisms. These include
`medications that inhibit apoptosis of the retinal ganglion cells, reduce
`oxidative stress, and optimize perfusion of the optic nerve.12-16 Many of
`these medications are clinically unproven and fall within the definition
`of CAM.
`Given the specific relevance of CAM to glaucoma, the potential for
`adverse effects, and the lack of disclosure of CAM use, it would be
`useful to study how patients with glaucoma use and perceive
`complementary and alternative therapies. By using a survey, it will be
`possible to obtain a cross-sectional analysis of the prevalence of CAM
`
`000006
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 7
`
`
`2009-present
`
`
`2008-present
`
`
`2008-present
`
`
`
`
`
`
`2008-2011
`
`
`use, the demographics of patients who use CAM, and the attitudes and
`beliefs of these patients.
`
`
`Impact and Incorporation of Canadian Glaucoma Guidelines in Clinical Practice
`(Co-Principal Investigator)
`The Canadian Glaucoma Guidelines were published in June 2008. In
`order to assess the impact and incorporation of the guidelines into
`clinical practice surveys of Canadian ophthalmologists will be
`conducted both prior and following an education session reviewing the
`guidelines to determine prior knowledge of the guidelines and impact on
`clinical decisions. Education sessions will be assessed as a method for
`disseminating future guidelines.
`
`Risk Factors in Glaucoma (Principal Investigator)
`Two multi-center Canadian studies. One to describe the prevalence and
`distribution of risk factors in subjects with either newly diagnosed open
`angle glaucoma or ocular hypertension. The secondary goal is to
`describe the severity of disease at time of diagnosis and investigate why
`subjects are referred for evaluation. Involvement in this study includes
`designing and writing the protocol, being a recruiting center, and the
`optic disc reading center. The goal is to enroll 400 subjects from 30
`centers.
`The second study is the E. A. Baker multi-centre study of risk factors
`for the progression of open-angle glaucoma. A prospective, 5 year
`study to characterize the risk factors, ocular and systemic, associated
`with the progression of glaucoma. To identify sub-groups of patients
`with regard to the type of progression to determine which are likely to
`and not likely to benefit from intraocular pressure reduction.
`Publications 37 and 49 are related to this work.
`My interest in this area was recognized with invited membership in the
`Glaucoma Clinical Practice Guidelines Expert Committee of the
`Canadian Ophthalmological Society for which I have written the
`Glaucoma Clinical Practice Guidelines for the Diagnosis of Glaucoma
`which includes an evidence-based review of risk factors for glaucoma.
`The guidelines are expected to be published in February 2009.
`
`Steroid induced IOP Elevation (Co-Principal Investigator)
`Steroids are known to elevated IOP in some individuals. The effect of
`steroids on IOP has not been previously studied in the early post-op
`period following glaucoma drainage devices and when applied by
`inhalation as used in allergic rhinitis.
`A prospective randomized double blind study of topical steroids versus
`NSAID following Ahmed valve surgery is currently underway to
`evaluate the rate of early post-operative IOP spikes.
`A prospective randomized double blind study of nasal steroid spray
`versus a placebo in glaucoma patients with allergic rhinitis will evaluate
`the possibility of steroid induced glaucoma by a nasal steroid spray.
`
`Sterile cover for G-probe (Principal Investigator)
`We have previously shown that energy transmission is maintained after
`repeated use of the G-probe for transscleral cyclophotocoagulation. The
`device however is designated as single use due to sterility issues related
`to the design of the footplate. We evaluated the use of a disposable
`barrier to in terms of both mechanical and clinical efficacy.
`
`
`000007
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 8
`
`2007-present
`
`2005 – present
`
`Conflicts of Interest (Principal Investigator)
`Industry bias in ophthalmology has not been previously studied. A
`review of publications comparing the hypotensive efficacy of topical
`prostaglandins found evidence of industry bias. This work was
`presented at the Association for Research in Vision and Ophthalmology
`in Fort Lauderdale May 2008, the 50th Annual Research Day at the
`University of Toronto in May 2008 and the Canadian Ophthalmological
`Society Meeting in June 2008 where it was awarded 3rd place for the
`COS Award for Excellence in Ophthalmic Research and is publication
`#50.
`As follow-up to this study a review of randomized control trials
`comparing the results of outcomes for sponsors versus competitors of
`the various prostaglandin analogues is underway. Finally a review of
`ophthalmology journals’ disclosure policies is currently completed and
`the manuscript has been submitted to Ophthalmology (publication
`#65).
`
`Glaucoma Drainage Devices (Co-Investigator)
`Studies evaluating the long-term results of Ahmed valve surgery and
`describing complications in various sub populations including uveitic
`glaucoma, second valve surgery and pre-operative IOP <20 mmHg.
`Publications 33, 48, 51, 52, 56 and 58 are related to this work.
`
`Digital ocular massage is a recognized procedure to improve filtration
`following trabeculectomy surgery. Given the variability in pressure
`applied by individuals a prospective trial of a novel device post-
`trabeculectomy was conducted. This work was awarded 1st prize for
`best poster at the 47th Annual Research Day for the Department of
`Ophthalmology and Vision Sciences at the University of Toronto in
`2005. This work was followed by studying the effect of digital ocular
`massage during the hypertensive phase in glaucoma drainage device
`surgery in both a retrospective and prospective manner, publications
`42, 43 and 60. These are the first publications on digital ocular
`massage in glaucoma drainage devices and found this procedure to be
`of benefit in this type of surgery. My interest in this area was
`recognized by an invitation to write a book chapter on Massage:
`techniques and complications in the text Glaucoma Surgery.
`
`An international multicenter study titled Ahmed versus Baerveldt
`comparison (ABC) study is underway comparing the long-term (5 year)
`safety and efficacy of the Ahmed FP-7 implant and the 350-mm2
`Baerveldt implant in patients who are undergoing aqueous shunt
`implant surgery. This is an international multicenter study with a total
`enrollment of 275 subjects from 18 investigators. Each site was to
`enroll 15 subjects. I enrolled 24 subjects making the Toronto Western
`Hospital was the highest recruiting center for this study.
`
`A mini glaucoma shunt, ExPRESS shunt, has recently been marketed as
`an alternative to glaucoma drainage surgery. Current we are conducting
`a prospective randomized controlled study comparing the efficacy and
`safety of the ExPRESS shunt to conventional trabeculectomy surgery.
`
`2002-present
`
`Rates and Cost of Managing Glaucoma in Ontario and Canada (Principal
`Investigator)
`
`000008
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`page 9
`
`Evaluation of the cost of managing glaucoma patients and to compare
`differences based on severity of disease as assessed by visual field
`parameters and the physicians’ assessment. Publications related to this
`work are #s 25, 30 and 34.
`
`Investigation of evolving trends in various surgical procedures
`including cataract surgery, filtration surgery and laser trabeculoplasty.
`Understanding trends is important for future planning of health care
`delivery which is especially important for glaucoma which is
`recognized as under serviced in Ontario. In addition possible
`influences on trends including the introduction of new medical
`therapies in glaucoma management and possible economic factors are
`being studied. Publications 35, 36, 40 and 46 are related to this work.
`The presentation Glaucoma laser and surgical procedure rates in
`Canada: a long-term profile was awarded Glaucoma Society
`nominated poster (a total of 10 posters out of 475 received this
`distinction) at the 2007 World Glaucoma Congress in Singapore.
`I was invited to write the editorial Economics of selective laser
`trabeculoplasty as primary therapy for glaucoma, CJO 41:419-20,
`2006 and to lecture at the World Glaucoma Congress in Singapore in
`2007 on Lasers in Glaucoma. Using the data from these studies I
`successfully revised the OHIP fee schedule for glaucoma, which had
`never been addressed previously. This involved both the updating of
`the reimbursement schedule and the introduction of 4 new glaucoma
`codes. Glaucoma specialists in Quebec have asked for my assistance
`with similar efforts in their province.
`
`Compliance in Glaucoma (Principal Investigator)
`Multi-center study to document prevalence and evaluate possible risk
`factors of non compliance and improper drug administration technique
`in glaucoma patients. This initial work is publication 47.
`Future plans for compliance study include a multi-center study to
`determine the effect of instituting a glaucoma educational program to
`improve compliance. This study received peer reviewed funding and
`media coverage in OSN SuperSite.
`
`Imaging Technologies for Optic Nerve Evaluation (Co-Principal Investigator)
`Imaging technologies are playing an increasing role in the clinical
`management of glaucoma despite limited understanding regarding
`interpretation for progression. A pilot study, publication 38, found
`poor results of HRT compared to expert assessment of paired
`stereodiscs. This study has been expanded to include a long-term
`prospective evaluation of HRT compared to stereodiscs and received
`peer review funding.
`
`Management of Combined Cataract and Glaucoma (Principal Investigator)
`To compare the IOP lowering of one versus two-site phaco-
`trabeculectomy surgery. Secondary outcome measures included
`surgical effect on endothelial cell counts, surgical complications and
`surgical time. In follow-up this cohort was also evaluated for
`correlation of bleb morphology with final IOP. Publications 45 and 51
`are related to this work.
`This study was presented at several meetings including oral
`presentations at the 3rd International Congress of Glaucoma Surgery in
`2006, the Association for Research in Vision and Ophthalmology in
`
`2005-present
`
`2003-present
`
`2003-present
`
`000009
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 10
`
`
`
`
`
`
`
`
`
`
`2002-2008
`
`
`
`
`
`
`2002-present
`
`
`
`
`2002
`
`
`
`
`
`
`
`
`
`
`
`
`1998-2004
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2007 and the American Glaucoma Society in 2007. This work
`received 1st prize for best poster, Correlation between the Indiana bleb
`appearance grading scale and intraocular pressure following phaco-
`trabeculectomy in 2008 at the Department of Ophthalmology,
`University of Toronto, 50th Annual Research Day.
`I have also been invited to lecture on this topic at the Glaucoma
`Subspecialty Day at the American Academy of Ophthalmology
`Meeting in Atlanta in November 2008 and the University of Toronto
`Walter Wright meeting on Advances in Ophthalmology in Toronto in
`December 2008. I have authored a monograph Surgical management
`of coesxisting cataract and glaucoma, Ophthalmology Rounds 2:1-6,
`2004 and authored two book chapters Combined cataract and
`glaucoma surgery in Glaucoma Surgery and One-site combined
`surgery / two-site combined surgery in Glaucoma, First Edition. This
`latter chapter included creating a surgical video for combined cataract
`and glaucoma surgery. Most recently I have written the Canadian
`guidelines for Combined Cataract and Glaucoma for the Canadian
`Ophthalmological Society. This work has received media publications
`in Ophthalmology Times September 1, 2007, Eye World Magazine July
`2007 and OSN SuperSite July 17, 2008.
`Since publication of this study other publications have appeared in the
`literature. A meta-analysis of the current literature on the efficacy of
`one- versus two-site phacotrabeculectomy is currently underway.
`
`Anesthesia Techniques for Glaucoma Surgery (Co-Principal Investigator)
`
`To evaluate lidocaine 2% jelly topical anesthesia for trabeculectomy
`surgery and compare to sub-Tenon’s anesthesia. This cohort was again
`evaluated in 2007 to determine long-term effect on IOP outcome. This
`work resulted in publications 28 and 57.
`
`Blood Flow in Glaucoma (Co-Investigator)
`The canon laser blood flowmeter is currently the only technology to
`quantitatively measure ocular blood flow. The effect of dorzolamide
`on retinal blood flow is being evaluated. In addition we have a unique
`system which can deliver isoxic hypercapnia and the effect of this
`technology is being compared in normals, progressive glaucomas and
`glaucomas pre and post treatment. Publication 29 is related to this
`work. This work was also recognized at the 2007 World Glaucoma
`Congress in Singapore where it was awarded the Glaucoma Society
`nominated poster (a total of 10 posters out of 475 received this
`distinction) and a book chapter Optic nerve blood flow for Textbook on
`glaucoma management is currently in press.
`
` Data processing of the SITA standard algorithm compromises the advantage
`of the faster patient testing time (Principal Investigator)
`
`To compare the total time taken to complete a 24-2 visual field test
`
`using the Humphrey Visual Field Analyzer III as compared to SITA.
`
`In addition each individual component of the testing procedure was
`
`evaluated. Publication 32 is related to this work.
`
`
`Evaluation of Genes in Glaucoma (Collaborator)
`Molecular screening of congenital glaucomas to establish phenotype-
`genotype correlations. To define the role of the myocilin gene in the
`Toronto adult glaucoma population. Publication 12 confirms previous
`reports of a 2-4% frequency of mutations in this gene which was
`
`
`000010
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 11
`
`originally determined in a Midwestern American population. The
`discovery of the gene in a pedigree initially allows for the close
`monitoring of carriers for the development of glaucoma. Further
`studies of the role of the protein encoded by myocilin will aid in the
`treatment of the leading cause of blindness in developed nations,
`glaucoma. Publications include #s 12, 18, 20, 21 and 31.
`
`
`
`
`Long term safety study of latanoprost (Principal Investigator)
`This study is a multinational, open-label, randomized comparison of
`latanoprost and “usual care”. The objectives of the study are to
`compare the frequency of side effects between the two groups, to
`follow serious adverse drug reactions throughout the study period, and
`to identify any possible long-term adverse consequences of increased
`iris pigmentation.
`
`Sleep related risk factors in progressive glaucoma (Collaborator)
`To investigate the relationship between the deterioration of vision in
`glaucoma and the way variables, such as blood pressure and breathing
`change during the different stages of sleep. Currently the effect of head
`position on IOP during sleep in progressive glaucomas is being studied.
`
`
`
`
`
`1999-2004
`
`
`1998-present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2. RESEARCH AWARDS
`
`
`
`
`
`October 1994 (5 years)
`
`
`i. Peer Reviewed
`1. Canadian National Institute for the Blind/
` E. A. Baker Foundation
`
`Total Amount: $147,500.00
`
`Co Principal Investigators: G. E. Trope, Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: E. A. Baker multi-centre study, risk factors on the progression of open-angle
`
`glaucoma
`
`2. Glaucoma Research Society of Ontario
`
`Total Amount: $26,989.68
`
`Principal Investigator: Y. M. Buys
`
`Departments of Ophthalmology and Vision Sciences and Physiology, University of Toronto
`
`Title: (-)-Deprenyl rescues retinal ganglion layer cells after optic nerve crush in adult rats
`
`3. Glaucoma Research Society of Canada
`
`Total Amount: $8 500
`
`Principal Investigators: C Birt, IK Ahmed
`
`Co Investigators: Toronto Area Glaucoma Society
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Prostaglandin efficacy and safety study undertaken by race (PRESSURE)
`
`4. Glaucoma Research Society of Canada
`
`Total Amount: $12 500
`
`Principal Investigators: C Birt, IK Ahmed
`
`Co Investigators: Toronto Area Glaucoma Society
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Prostaglandin efficacy and safety study undertaken by race (PRESSURE)
`
`5. Canadian Institutes of Health Research
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`November 1994 (2 years)
`
`May 2003 (1 year)
`
`January 2005 (1 year)
`
`March 2006 (4 years)
`
`
`
`000011
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 12
`
`Total Amount: $240 040
`Principal Investigator: C Hudson
`Co Principal Investigators: J Flanagan, GE Trope, YM Buys
`Department of Ophthalmology and Vision Sciences
`Title: Retinal vascular reactivity in primary open angle glaucoma
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`April 2006 (2 years)
`
`April 2006 (2 years)
`
`May 2009 (1 year)
`
`June 2009 (1 year)
`
`
`
`February 2010 (5 years)
`
`
`
`
`
`
`
`6. Glaucoma Research Society of Canada
`
`Total Amount: $12,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Utility of Heidelberg Retina Tomography II
`
`7. Glaucoma Research Society of Canada
`
`Total Amount: $10,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Administration technique and compliance in topical drug therapy of glaucoma
`
`8. Glaucoma Research Society of Canada
`
`Total Amount: $11,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Utility of Heidelberg Retina Tomography II
`
`9. Canadian Glaucoma Society-Merck Frosst Canada Best Research Proposal
`
`Total Amount: $3,000
`
`Principal Investigator: Y M Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Alternative therapies for glaucoma
`
`
`10. Ontario Research Fund
`
`Total Amount: $2,478,074
`
`Principal Investigator: C Hudson
`
`Co Investigators: JG Flanagan, K Bizheva, MH Brent, YM Buys, RG Devenyi, JA Fischer, WC Lam, GE
`Trope
`Title: Retinal oxygen saturation, blood flow, vascular function and high resolution morphometric imaging
`in the living human eye
`
`
`
`
`11. Canadian Ophthalmological Society
`
`Total Amount: $50,000
`
`Principal Investigators: YM Buys, K Damji, P Rafuse
`
`Title: Evaluation of the Canadian Glaucoma Guidelines
`
`12. Canadian National Institute for the Blind
`
`Total Amount: $4,000
`
`Principal Investigator: YM Buys
`
`Title: Outcomes of the CNIB Baker grants from 1998 to 2009
`
`13. Canadian Glaucoma Clinical Research Council-CNIB
`
`Total Amount: $10 000
`
`Principal Investigator: YM Buys
`
`Title: The effect of body posture on intraocular pressure in progressive glaucoma
`
`14. Canadian Glaucoma Clinical Research Council-CNIB March 2012 (1 year)
`
`Total Amount: $7 500
`
`
`
`
`
`
`
`April 2010 (1 year)
`
`
`
`June 2010 (1 year)
`
`Nov 2011 (1 year)
`
`
`
`000012
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 13
`
`Principal Investigator: YM Buys
`Title: Effect of obesity on intraocular pressure changes related to head and body position
`
`
`
`
`
`May 2015 (1 year)
`
`
`
`
`15. Canadian Glaucoma Society-Merck Frosst Canada Best Research Proposal June 2012 (1 year)
`
`Total Amount: $3,000
`
`Principal Investigator: Y M Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Effect of obesity on intraocular pressure changes related to head and body position
`
`16. Glaucoma Research Society of Canada
`
`Total Amount: $20,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: A Prospective study to compare the effect of continuous positive airway pressure versus a
`mandibular advancement oral appliance on intraocular pressure in patients with obstructive sleep apnea and
`open angle glaucoma
`
`
`17. DOVS Pilot Research Grant Competition
`
`Total Amount: $10,000
`
`Co-Principal Investigators: YM Buys, GE Trope
`
`A prospective study to compare the effects of continuous positive airway pressure versus a mandibular
`advancement oral appliance on intraocular pressure in patients with obstructive sleep apnea and open angle
`glaucoma
`
`
`
`ii. Non Peer Reviewed
`
`1. Pharmacia Ophthalmics
`
`Total Amount: $32,502.00
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Long-term effect of latanoprost on intraocular pressure in normal tension glaucoma.
`
`A randomized, double-masked placebo-controlled study
`
`
`2. Pharmacia & Upjohn
`
`Total Amount: $8,000.00
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`Title: A randomized, 5-year postmarketing safety study of Xalatan compared to “usual care” in patients
`with open angle glaucoma or ocular hypertension
`
`
`
`
`
`
`
`
`
`
`
`
`
`January 1997 (2 years)
`
`June 1999 (5 years)
`
`
`
`3. Merck Frosst
`
`Total Amount: $3,650.00
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Cosopt IOP Treatment Evaluation: CITE
`
`4. Merck Frosst Canada Inc.
`
`Total Amount: $10,000
`
`Principal Investigator: C Hudson
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Ocular blood flow measured by HRF and CLBF in newly diagnosed and early glaucoma patients
`before and after instillation of Dorzolamide 2%
`
`
`
`
`
`
`
`
`
`
`
`
`
`May 2001 (1 year)
`
`February 2004 (2 years)
`
`
`
`5. Pfizer Canada Inc.
`
`Total Amount: $5, 000
`
`
`
`
`
`
`
`December 2004 (1 year)
`
`
`
`000013
`
`

`

`Curriculum Vitae of Yvonne M. Buys
`
`
`
`page 14
`
`
`
`
`
`
`
`
`
`
`June 2005 (1 year)
`
`Principal Investigator: Y. M. Buys
`Department of Ophthalmology and Vision Sciences
`Title: Resident Research Grant for: A prospective, randomized
`comparison of one-site and two-site phacotrabeculectomy.
`
`
`6. Pfizer Canada Inc.
`
`Total Amount: $5,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: Diurnal changes in optic nerve topography, intraocular pressure and central corneal thickness in
`patients with untreated, newly diagnosed glaucoma
`
`
`
`
`
`
`
`
`
`
`
`
`
`June 2005 (1 year)
`
`October 2005 (2 years)
`
`
`
`7. Pfizer Canada Inc.
`
`Total Amount: $5,000
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: The effect of pupil dilation on driving vision in patients with and without cataracts and/or glaucoma
`
`
`
`8. Allergan
`
`Total Amount: $4 800
`
`Principal Investigator: Y. M. Buys
`
`Department of Ophthalmology and Vision Sciences
`
`Title: A masked histological evaluation of trabecular meshwork specimens collected from trabeculectomy
`patients with primary open-angle glaucoma treated with bimatoprost 0.03% ophthalmic solution once-daily
`(QD) for at least two years compared with primary open-angle glaucoma patients treated with other topical
`ophthalmic IOP-